Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Q2 net loss widens to $36.4 million; cash totals $472.2 million

Negative Impact 3 of 5 earnings Written later

Avalo Therapeutics reported a second-quarter 2026 net loss of $36.4 million, up $15.6 million from a year earlier, as research and development and general and administrative expenses rose. The company reported $472.2 million in cash, cash equivalents and investments as of June 30, 2026, which it says should fund operations into 2029, and plans to start a Phase 3 trial of abdakibart in hidradenitis suppurativa in the first half of 2027.

Key points

  • Q2 2026 net loss was $36.4 million versus $20.8 million in Q2 2025; net loss per share was $0.83 versus $1.92, on 43,602,044 weighted average shares versus 10,829,760.
  • R&D expenses were $23.4 million, up $9.3 million, including a $10.0 million development milestone for abdakibart; G&A expenses were $8.1 million, up $2.9 million.
  • Cash, cash equivalents and investments were $472.2 million at June 30, 2026, with the company expecting runway into 2029.
  • Plans to initiate a registrational Phase 3 program for abdakibart in HS in the first half of 2027; AVTX-010 IND submission planned for the first half of 2027.

The filing

CompanyAvalo Therapeutics, Inc. (AVTX)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:01 AM ET
Accession number0001534120-26-000048

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.